The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice
- PMID: 36875915
- PMCID: PMC9982215
- DOI: 10.1016/j.jaccao.2022.10.009
The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice
Keywords: epidemiology; guidelines; outcomes.
Conflict of interest statement
Dr Leong has received consultancy and speaker fees from Abbvie, Ferring Pharmaceuticals, Janssen, Myovant Sciences, Novartis, Pfizer, Sanofi, Tolmar, AstraZeneca, and Paladin related to prostate and myeloproliferative neoplasm cardio-oncology; and research support from Novartis. Dr Mukherjee has reported that he has no relationships relevant to the contents of this paper to disclose.
References
-
- Lyon A.R., López-Fernández T., Couch L.S., et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 2022;43(41):4229–4361. doi: 10.1093/eurheartj/ehac244. - DOI - PubMed
-
- Thavendiranathan P., Negishi T., Somerset E., et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77:392–401. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Medical